Trabectedin arrests a doxorubicin-resistant PDGFRA-activated liposarcoma patient-derived orthotopic xenograft (PDOX) nude mouse model

Tasuku Kiyuna, Yasunori Tome, Takashi Murakami, Kei Kawaguchi, Kentaro Igarashi, Kentaro Miyake, Masuyo Miyake, Yunfeng Li, Scott D. Nelson, Sarah M. Dry, Arun S. Singh, Tara A. Russell, Irmina Elliott, Shree Ram Singh, Fuminori Kanaya, Fritz C. Eilber, Robert M. Hoffman

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: Pleomorphic liposarcoma (PLPS) is a rare, heterogeneous and an aggressive variant of liposarcoma. Therefore, individualized therapy is urgently needed. Our recent reports suggest that trabectedin (TRAB) is effective against several patient-derived orthotopic xenograft (PDOX) mouse models. Here, we compared the efficacy of first-line therapy, doxorubicin (DOX), and TRAB in a platelet-derived growth factor receptor-α (PDGFRA)-amplified PLPS. Methods: We used a fresh sample of PLPS tumor derived from a 68-year-old male patient diagnosed with a recurrent PLPS. Subcutaneous implantation of tumor tissue was performed in a nude mouse. After three weeks of implantation, tumor tissues were isolated and cut into small pieces. To match the patient a PDGFRA-amplified PLPS PDOX was created in the biceps femoris of nude mice. Mice were randomized into three groups: Group 1 (G1), control (untreated); Group 2 (G2), DOX-treated; Group 3 (G3), TRAB-treated. Measurement was done twice a week for tumor width, length, and mouse body weight. Results: The PLPS PDOXshowedresistance towards DOX. However, TRAB could arrest the PLPS (p<0.05 comparedto control; p<0.05 compared to DOX) without any significant changes in body-weight. Conclusions: The data presented here suggest that for the individual patient the PLPS PDOX model could specifically distinguish both effective and ineffective drugs. This is especially crucial for PLPS because effectivefirst-line therapy is harder to establish if it is not individualized.

Original languageEnglish
Article number840
JournalBMC Cancer
Volume18
Issue number1
DOIs
Publication statusPublished - 2018 Aug 20

Keywords

  • Liposarcoma
  • PDGFRA amplification
  • PDOX
  • Patient-derived orthotopic xenograft
  • Precision medicine
  • Trabectedin

ASJC Scopus subject areas

  • Oncology
  • Genetics
  • Cancer Research

Fingerprint Dive into the research topics of 'Trabectedin arrests a doxorubicin-resistant PDGFRA-activated liposarcoma patient-derived orthotopic xenograft (PDOX) nude mouse model'. Together they form a unique fingerprint.

  • Cite this

    Kiyuna, T., Tome, Y., Murakami, T., Kawaguchi, K., Igarashi, K., Miyake, K., Miyake, M., Li, Y., Nelson, S. D., Dry, S. M., Singh, A. S., Russell, T. A., Elliott, I., Singh, S. R., Kanaya, F., Eilber, F. C., & Hoffman, R. M. (2018). Trabectedin arrests a doxorubicin-resistant PDGFRA-activated liposarcoma patient-derived orthotopic xenograft (PDOX) nude mouse model. BMC Cancer, 18(1), [840]. https://doi.org/10.1186/s12885-018-4703-0